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The Surgeon and the Patient with Cancer:
The Development of Surgical Oncology
Angelos A. Kambouris, M D *

to become familiar with radiotherapy, its capabilities
and its side effects, in order to serve the best interests of
their patients. Cooperative teams of surgeons and radiotherapists were established, and as the results of their
combined modalities became publicized, traditional
surgical approaches were modified. C o m b i n i n g radiotherapy with surgery for cancers of the breast, larynx,
and other head and neck cancers, pelvic malignancy,
and cancer of the esophagus are some examples of this
approach. The best example of such cooperation was
represented by surgeons ( M c C o m b , Jesse, White) and
radiotherapists (Fletcher, Lindberg) at the M . D. Anderson Hospital in Houston, Texas.

T h e role o f t h e surgeon in treating patients with cancer
has changed over the past 30 years. For many years the
surgeon was traditionally viewed as the key clinician in
treating cancer. This role was strengthened by the
development of the concept of local-regional resections
for treating cancers o f t h e breast (Halsted, 1894), rectum
(Miles, 1907), and neck (Crile, 1906). Over the next 40
years this concept was enlarged to include treatment of
urological and gynecological cancers. The parallel
d e v e l o p m e n t of institutions for categorical cancer
treatment and technological advancements in anesthesia and blood replacement enhanced the role of the
surgeon in cancer treatment, which culminated in the
1950s. The emphasis at that time was on extensive operations termed " r a d i c a l " or "supraradical" because of
their magnitude as well as the effects on the functionality of the patients. The objective was to conquer cancer
through an ever-expanding surgical attack. Examples of
this approach can be found in operations for oropharyngeal and thyroid cancers, supraradical and extended
radical operations for breast cancer, extended total gastrectomy for stomach cancer and major disarticulations,
and even " h e m i c o r p o r e c t o m y " for treating melanoma
of the extremities or sarcomas of the soft somatic tissues
and bones. Unusual expertise in surgical techniques was
concentrated in a few specialized cancer institutions;
the writings of George T. Pack, Jr, Hayes M a r t i n , and
Cushman Haagensen, among many, were instrumental
in affirming the role of the surgeon in the cancer field.
However, since 1950, several new developments have
modified or totally changed the surgeon's part in treating patients with cancer.

However, the major factors in bringing about a reassessment of the surgeon's role in the cancer field have
been the development and proliferation of anti-neoplastic
agents, and to a lesser degree, the revival of the interest
in immunotherapy. The discovery of the anti-neoplastic
effectiveness of nitrogen mustard during W o r l d War II
opened new vistas in the ongoing effortsto cure cancer.
Since that discovery, thousands of compounds have
been tested to assess their anti-neoplastic properties,
and research in cellular and molecular biology has
increased our understanding of cancer cells and their
response to drugs. Also, the inadequately explored
potential of immunotherapy for cancer treatment has
come to the forefront. Chemotherapy alone or combined with other modalities has been employed to cure
certain cancers, such as leukemias, lymphomas, and sarcomas. In solid tumors its main function has been to treat
patients with symptomatic metastases and, more recently
in the adjuvant setting, to eliminate micrometastatic disease and enhance the role of traditional (usually surgical) therapy. Because of the many anti-neoplastic com-

The advent of megavoltage radiation added precision
and effectiveness in tumor destruction, while it spared
or minimized injury to normal tissues. Radiotherapy
thus claimed an increasing role in treating localized
cancers, either alone or combined with surgical procedures. Combination treatment schemes were devised to
increase cancer control and minimize disability and dysfunction f r o m extensive operations. Many surgeons had
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pounds, it was quickly recognized that appropriate
testing and accurate scientific recording of their effectiveness as well as of side effects and complications
w o u l d be needed. Well-controlled mechanisms for
phased introduction of new agents was established and
implemented through multi-institutional collaboration.
To that e n d , cooperative groups were f o r m e d , and randomized clinical trials were established on a national or
international basis to test multiple drugs and their c o m binations on large numbers of patients.

arterial injections of nitrogen mustard. Later, in 1958
Creech (2), a surgeon in New Orleans, and Stehlin in
1960 (3), a surgeon in Houston, developed and expanded
the concept of regional chemotherapy by transferring
experience with extracorporeal circulation from cardiac
surgery to cancer treatment, using isolation perfusion of
the extremities and other regions of the human body.
Because isolation perfusion permitted cancer-bearing
areas to be exposed to concentrated or even lethal
amounts of chemotherapeutic agents, effective tumor
control was enhanced, while the patient was protected
from systemic toxicity and myelosuppression. During
the same period, the concept of intermittent or continuous intraarterial infusion chemotherapy was developed and clinically employed by surgeons (4) and
medical oncologists (5). Regional chemotherapy, which
developed during the expanding era in medical oncology,
remains relatively unchanged except for new drug
combinations or the a d d i t i o n of radiotherapy and
hyperthermia.

Encouraged by massive publicity and unlimited funding,
these developments were accompanied by the growth
of new training programs to meet manpower needs. A
new subspecialty of clinical oncology arose, as internists
pursued two or more years ofadditional training to meet
training and credential requirements and to pass appropriate certification. They assumed leadership roles in
cancer-related affairs, including the total care of patients
with advanced cancers, and consultation and planning
for cancer programs, and treatment planning for patients
with early cancers. Although most patients continue to
present with surgically curable cancers, this new development has overshadowed the traditional role of the
surgeon in the cancer field; this despite the fact that
surgery remains the most effective means of treating
cancer, and that improved cure rates resulting from the
expanded role of medical oncology have been difficult
to document.

Because of the continued emphasis on cancer biology
and on the role of chemotherapy during the 1950s,
surgeons became involved in clinical and basic research
studies. Local w o u n d applications, intraluminal irrigations, or systemic administration of cancer chemotherapeutic agents in the perioperative period were some of
the techniques surgeons used in adjuvant treatment of
patients w i t h localized, surgically treatable cancer.
Surgical adjuvant chemotherapy programs were slowly
but methodically developed in the late 1950s and found
nationwide appeal in the 1960s and 1970s. The model of
such a program is the National Surgical Adjuvant Breast
Project for studying the biology and treatment of breast
cancer, under the sustained leadership of a surgeon,
B. Fisher.

In response to these developments, surgical approaches
have changed considerably. Some changes occurred
because more extensive operations failed to improve
cure rates. Supraradical mastectomy was abandoned,
and extended total gastrectomy was replaced with radical subtotal gastrectomy. Other surgical procedures
were modified, as understanding of the biology of
cancers improved, and earlier detection of neoplasms
became possible at a preinvasive or early invasive stage
where more precise but less extensive operations are
necessary. Controversies in treating breast, thyroid, and
lung cancers are prime examples.

Furthermore, surgeons have become more familiar with
the concepts of immunotherapy, the role of tumor
reductive operations, and the importance of using
multi-modality approaches to achieve better results
through more precise and less disabling operations. The
concept of limb salvage operations for sarcomas of the
extremities and the improved results in pediatric solid
tumors are examples of such collaborative approaches.

The main changes, however, occurred in response to
new developments in cancer treatment. Surgeons rapidly
accepted and adopted the use of anti-neoplastic compounds. They were thus able to observe at firsthand the
destructive effects of chemotherapeutic agents on malignant neoplasms and also the attendant side effects and
toxicity on patients. In efforts to minimize such undesirable side effects while maximizing therapeutic benefits, surgeons modified the application of chemotherapy.
In 1950, Klopp (1), a surgeon, introduced the concept of
regional chemotherapy by employing fractionated intra-

Probably the most impressive change occurred when
surgeons became active participants in multi-institutional,
controlled clinical trials. Such massive participation
represented a change in philosophy and awareness
among surgeons, brought about in part by the efforts of
medical oncologists to i m p r o v e t h e somewhat stationary
results of surgical treatment for patients with Stage II
cancers. However, credit also goes to the surgeons w h o
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encouraged their patients to enter such clinical trials,
although they risked side effects and symptoms generated by a variety of treatment schemes w i t h o u t guarantee of therapeutic benefits. In response to these changes
in attitudes, trends, and service needs, it has become
necessary for surgeons to expand their basic training and
gain an understanding of chemotherapy, immunotherapy, radiation therapy, and hyperthermia, areas not
included in their traditional education.

ing to develop the surgical arm of the multi-disciplinary
attack against cancer. Establishing a surgical subspecialty
that w o u l d prepare surgeons appropriately at a level
comparable to that of their colleagues appeared attractive. While the cancer-oriented nonsurgical subspecialists supported this effort, the surgeons themselves for
various reasons have been slow to endorse such a need.
As part of this ongoing assessment and after input from
many professionals, a consensus conference was held in
1978 under the auspices of the National Cancer Institute.
It affirmed the belief that " t h e r e is a need for a subspecialty of surgical oncology, with members having sound
training in general surgery but additional training in
other specialties" (6) in order to complement their
knowledge in the field of cancer. Training guidelines
were established at that meeting, and the effort for
implementation continues.

This course of events has been a blueprint for professionals to develop recognized groups of specialists w h o
commit themselves to dealing with the issue, to develop
an educational program to assure adequate training, and
to develop a credentialing mechanism to evaluate and
appropriately certify those w h o complete such training.
While this has occurred in the subspecialties of radiation
oncology, gynecological oncology, and medical oncology, a subspecialty of surgical oncology is only lately
being discussed. A l t h o u g h many surgeons recognized
such need on their own and obtained additional training,
only recently has an organized approach to that need
been identified. Educational programsaimed at updating
surgical knowledge in the field of cancer have proliferated. The Commission on Cancer of the American
Collegeof Surgeons has been influential in incorporating
postgraduate courses in cancer at each annual convention and at many regional and local chapter meetings. In
response to public pressures, many consensus meetings
have been held to address changing concepts and
treatment approaches, many of them directly or indirectly
involving the surgeon. Surgical publications stressing
m u l t i - m o d a l i t y approaches a b o u n d . A n e t w o r k of
national centers was developed for consultation, referral,
or expert information for surgical and multi-modal treatment of cancer patients.

These intensified efforts to develop an identity within
the broad field of surgery are still in their formative
stages, and the role of the surgical oncologist is still
being d e f i n e d (7-13). Publications in the literature
emphasize sound surgical training, additional educational exposure in medical oncology, immunology,^
radiotherapy, pathology, and other disciplines, and the
ability to assume leadership roles in clinical, research,
and educational aspects affecting the role of surgeons in
the field of cancer. In that capacity, a surgical oncologist
would " c o m p l e m e n t rather than replace" (7) the surgeon in his or her traditional role. Furthermore, the
surgical oncologist would be able to represent surgical
interests among other subspecialists at a comparable
level. Viewed in its broad perspective, the need for a
subspecialty of surgical oncology becomes obvious. The
recognition of this need is best reflected by the fact that
many medical schools and academic centers have established well-structured divisions of surgical oncology (6)
and by the fact that the National Cancer Institute has
allocated modest funds to support research and development in surgical oncology.

This new role for the surgeon was facilitated in the early
1970s when the prestigious James Ewing Society, a multispecialty organization of traineesof the Memorial SloanKettering Cancer Center in New York, and for many
years the focus of exchange of scientific and clinical
informat ion in the cancer field, became the Society of
Surgical Oncology. Membership was opened to surgeons trained in other institutions but whose sole or
primary interest is the patient with cancer. The need to
reassess the role of the surgeon in the expanding field of
cancer-related activities had been obvious to the Society
for many years. Surgeons were underrepresented in
multi-specialty committees and policy-making activities
at hospital, local, and national levels, and were not, as a
consequence, being adequately recognized with fund-

It is evident from this brief review that the surgeon will
continue to play an important role in the cancer field, a
role that will become more demanding as it becomes
more complex. Whereas in past years the surgical
-emphasis was on technical ability, technical expertise in
surgery, biology, and interdisciplinary studies will bethe
hallmark of tomorrow's surgical oncologist. Such adaptation will assist in maintaining the surgeon as a leader in
a constantly changing and not always clear-cut field and
will promulgate new concepts of surgical and nonsurgical applications of cancer treatment to surgeons in train158
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ing. Most of all, it will contribute to optimal patient care
by strengthening the ability of the surgeon to select

treatment approaches based on scientific knowledge as
well as technical expertise.
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